Screener / SEC EDGAR /CIK 0001727196 /10-K filed Mar 3, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Scholar Rock Holding Corp SRRK

Compare with peers Embed
FY2025 at a glance

Free cash flow down to -$300.6M

XBRL, from each 10-K
RevenueStatements
$0
FY2017FY2025
Net incomeStatements
-$377.9M from -$246.3M in FY2024
FY2017FY2025
Free cash flowStatements
-$300.6M from -$201.0M in FY2024
FY2017FY2025
EPS (diluted)Statements
$-3.29 from $-2.47 in FY2024
FY2017FY2025
Total debtStatements
$99.7M from $50.1M in FY2024
FY2017FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (30)
EPS (ttm)
-3.23
Sales (ttm)
570K
Net income (ttm)
-413.6M
Sales growth
-
EPS growth
-
Sales Q/Q
-
Free cash flow
-309.9M
Gross margin
-
Oper. margin
n/m
Net margin
n/m
FCF margin
n/m
ROE
n/m
R&D / sales
-
Dividend
-
Debt/Eq
1.16
Curr. ratio
5.41
Cash
366.3M
Op. cash flow (ttm)
-309.7M
EBITDA
-383.0M
Net debt
-170.1M
Quick ratio
5.41
Interest cover
-55.80
FCF after stock pay
-376.2M
Shares out.
122.0M
Shares Y/Y
+14.9%
Book / share
1.38
Cash / share
3.00
Sales / share
0.00
Asset turnover
0.00

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2018 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 0 Net income -377.9M
FY2018 revenue 0 · Revenues, 0001558370-19-002252 FY2018 net income -49.3M · NetIncomeLoss, 0001558370-20-002536 0 FY2018 FY2019 revenue 20.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-21-002641 FY2019 net income -51.0M · NetIncomeLoss, 0001558370-21-002641 20.5M FY2019 FY2020 revenue 15.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-22-002928 FY2020 net income -86.5M · NetIncomeLoss, 0001558370-22-002928 15.4M FY2020 FY2021 revenue 18.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-23-002992 FY2021 net income -131.8M · NetIncomeLoss, 0001558370-23-002992 18.8M FY2021 FY2022 revenue 33.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001558370-24-003540 FY2022 net income -134.5M · NetIncomeLoss, 0001558370-24-003540 33.2M FY2022 FY2025 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001104659-26-022551 FY2025 net income -377.9M · NetIncomeLoss, 0001104659-26-022551 0 FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2017 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -24.1% a year FY2020 $8.48 to FY2025 $2.14, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$3.29$2.14-$2.62
Dec 31, 2024 -$2.47$3.69-$2.01
Dec 31, 2023 -$1.99$2.70-$1.74
Dec 31, 2022 -$2.26$4.37-$2.24
Dec 31, 2021 -$3.59$4.69-$3.60
Dec 31, 2020 -$2.81$8.48-$2.09
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $385.1M
  • − All liabilities $158.8M
  • = Net current asset value $226.4M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $245.5M
  • = Tangible book value $245.5M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

SRRK against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Debt / equity (less is better)
1.160.42
1.1681st of 108 · median 0.69
SRRK and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
SRRK Scholar Rock Holding Corp$570K -----1.16
OCUL Ocular Therapeutix, Inc$50.4M -18.5%87.3%-648.6%-74.1%-530.0%0.17
ROIV Roivant Sciences Ltd.$41.1M -71.6%--838.2%-8.6%-81.2%-
IDYA IDEAYA Biosciences, Inc.$36.5M ----38.5%-957.4%-
CRSP CRISPR Therapeutics AG$25.2M -90.6%---27.7%-0.36
CGON CG Oncology, Inc.$6.2M +255%---24.0%-0.00
All 162 companies in the group

Profitability

  • Net margin below the peer median
    -72563.2% vs 6.8%
  • Return on equity below 15%
    -245.2%
  • A profit in 0 of 6 years
Net margin, FY2018 to FY2025: -248.9% to -405.2%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -55.8× interest expense
  • Debt larger than equity
    Debt / equity 1.16 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 5.41
  • More cash than debt
    Net cash $214.1M
Debt / equity at each year end, FY2018 to FY2025: 0.00 to 0.41

Cash and shareholders

  • Free cash flow positive in 1 of 6 years
    −$300.6M last year
  • Share count up over 3 years
    +86.6%
Free cash flow, FY2018 to FY2025: 23.1M to -300.6M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

SRRK's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 9. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue0
FY2017: -FY2018: 0FY2019: 20.5MFY2020: 15.4MFY2021: 18.8MFY2022: 33.2MFY2023: -FY2024: -FY2025: 0 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income-377.9M
FY2017: -25.0MFY2018: -49.3MFY2019: -51.0MFY2020: -86.5MFY2021: -131.8MFY2022: -134.5MFY2023: -165.8MFY2024: -246.3MFY2025: -377.9M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow-300.6M
FY2017: -22.1MFY2018: 23.1MFY2019: -66.2MFY2020: -64.4MFY2021: -132.0MFY2022: -133.8MFY2023: -145.3MFY2024: -201.0MFY2025: -300.6M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay-376.2M
FY2017: -23.6MFY2018: 17.9MFY2019: -74.2MFY2020: -75.5MFY2021: -155.2MFY2022: -161.5MFY2023: -172.4MFY2024: -237.7MFY2025: -376.2M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)-3.29
FY2017: -15.30FY2018: -3.15FY2019: -1.85FY2020: -2.81FY2021: -3.59FY2022: -2.26FY2023: -1.99FY2024: -2.47FY2025: -3.29 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares114.7M
FY2017: -FY2018: -FY2019: -FY2020: 30.7MFY2021: 36.7MFY2022: 59.6MFY2023: 83.3MFY2024: 99.8MFY2025: 114.7M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Income statement

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue-020.5M15.4M18.8M33.2M--0
R&D19.9M36.3M54.2M74.1M108.5M124.4M121.9M184.6M208.4M
SG&A5.1M14.4M20.8M28.2M40.3M43.1M49.4M67.5M176.2M
Operating income-25.0M-50.7M-54.5M-86.9M-129.9M-134.4M-171.3M-252.1M-384.6M
Interest expense53K34K27K400K2.1M4.7M6.5M6.8M6.9M
Pretax income--------246.3M-377.7M
Net income-25.0M-49.3M-51.0M-86.5M-131.8M-134.5M-165.8M-246.3M-377.9M
EPS (diluted)-15.30-3.15-1.85-2.81-3.59-2.26-1.99-2.47-3.29
Diluted shares---30.7M36.7M59.6M83.3M99.8M114.7M
Depreciation & amortization669K807K1.3M1.5M2.6M3.0M2.8M1.9M1.7M
EBITDA-24.4M-49.9M-53.2M-85.4M-127.3M-131.4M-168.5M-250.1M-383.0M
Operating margin---266.2%-564.0%-690.5%-404.8%---
Net margin---248.9%-561.5%-700.5%-405.2%---
Revenue growth----24.8%+22.2%+76.4%---

Balance sheet

From EDGAR

Cash flow

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-21.7M24.6M-63.1M-60.3M-126.8M-132.7M-145.2M-200.9M-300.0M
Capital spending361K1.5M3.1M4.1M5.2M1.1M71K98K602K
Free cash flow-22.1M23.1M-66.2M-64.4M-132.0M-133.8M-145.3M-201.0M-300.6M
Stock-based pay (added back)1.5M5.2M8.0M11.2M23.1M27.7M27.1M36.6M75.6M
Free cash flow after stock pay-23.6M17.9M-74.2M-75.5M-155.2M-161.5M-172.4M-237.7M-376.2M
Debt raised---24.6M25.0M---24.7M
Debt repaid-667K365K-----25.5M
Investing cash flow17.7M-60.2M-62.2M-63.5M134.3M-171.7M41.1M-76.1M218.7M
Financing cash flow50.5M94.3M48.9M247.8M45.0M194.8M102.6M353.0M228.4M

Stock-based pay and leases

From EDGAR
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)1.5M5.2M8.0M11.2M23.1M27.7M27.1M36.6M75.6M
Stock-based pay / revenue--38.9%72.6%123.0%83.5%---
Operating lease cost--1.4M3.2M8.6M8.7M8.3M7.0M6.9M
Operating lease cash paid--1.3M2.1M8.9M9.2M9.1M8.1M7.4M
Right-of-use assets--4.4M32.3M25.4M18.5M11.4M15.6M10.4M
Operating lease liabilities--5.3M32.5M27.1M19.7M11.8M15.0M9.2M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SRRK/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.